{"success":true,"data":{"pressRelease":{"id":"157178","rtpr_id":"nGNX23pY3V-20260930","ticker":"CBNK","exchange":"NASDAQ","all_tickers":["CBNK","LFCR","MG","PEBO","UTZ"],"title":"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)","author":"Globe Newswire","published_at":"2026-09-30T18:04:02.107Z","article_body":"BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds\ninvestors of the following investigations. If you own shares and wish to\ndiscuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com)\nor Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no\ncost or financial obligation to you.\n\nCapital Bancorp, Inc. (Nasdaq – CBNK)\n\nUnder the terms of the Merger Agreement, Capital will be acquired by Peoples\nBancorp Inc. (“Peoples”) (Nasdaq - PEBO) whereby shareholders of Capital\nwill receive 1.11 shares of Peoples common stock for each share of Capital\ncommon stock. Based on Peoples' 20-day volume-weighted average closing price\nof $39.41 per share as of September 29, 2026, the aggregate transaction value\nis approximately $728.1 million, or $43.75 per share. The investigation\nconcerns whether the Capital Board breached its fiduciary duties to\nshareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/capital-bancorp-inc-nasdaq-cbnk/.\n\nLifecore Biomedical, Inc. (Nasdaq – LFCR)\n\nUnder the terms of the Merger Agreement, Lifecore Biomedical will be acquired\nby Webster Equity Partners for $6.28 per share in cash at closing plus one\nnon-tradable contingent value right (CVR) per share. The investigation\nconcerns whether the Lifecore Biomedical Board breached its fiduciary duties\nto shareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/lifecore-biomedical-inc-nasdaq-lfcr/.\n\nMISTRAS Group, Inc. (NYSE – MG)\n\nUnder the terms of the Merger Agreement, MISTRAS Group will be acquired by\naffiliates of H.I.G. Capital for $20.35 per share in an all-cash transaction,\nrepresenting an enterprise value of approximately $866 million, including\noutstanding debt. The investigation concerns whether the MISTRAS Group Board\nbreached its fiduciary duties to shareholders by failing to conduct a fair\nprocess, including whether the proposed transaction is paying fair value to\nshareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/mistras-group-inc-nyse-mg/.\n\nUtz Brands, Inc. (NYSE – UTZ)\n\nUnder the terms of the Merger Agreement, Utz will be acquired by Intersnack\nGroup GmbH & Co. KG (“Intersnack”) for $14.25 per share in cash\nrepresenting an enterprise value of approximately $2.9 billion. The\ninvestigation concerns whether the Utz Board breached its fiduciary duties to\nshareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/utz-brands-inc-nyse-utz/.\n\nBrodsky & Smith is a litigation law firm with extensive expertise representing\nshareholders throughout the nation in securities and class action lawsuits.\nThe attorneys at Brodsky & Smith have been appointed by numerous courts\nthroughout the country to serve as lead counsel in class actions and have\nsuccessfully recovered millions of dollars for our clients and shareholders.\nAttorney advertising. Prior results do not guarantee a similar outcome.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/aeea7200-7231-49dd-b4ba-ec680464b28c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX23pY3V-20260930","title":"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)","author":"Globe Newswire","ticker":"CBNK","created":"2026-09-30T18:04:02.107Z","tickers":["CBNK","LFCR","MG","PEBO","UTZ"],"exchange":"NASDAQ","article_body":"BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds\ninvestors of the following investigations. If you own shares and wish to\ndiscuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com)\nor Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no\ncost or financial obligation to you.\n\nCapital Bancorp, Inc. (Nasdaq – CBNK)\n\nUnder the terms of the Merger Agreement, Capital will be acquired by Peoples\nBancorp Inc. (“Peoples”) (Nasdaq - PEBO) whereby shareholders of Capital\nwill receive 1.11 shares of Peoples common stock for each share of Capital\ncommon stock. Based on Peoples' 20-day volume-weighted average closing price\nof $39.41 per share as of September 29, 2026, the aggregate transaction value\nis approximately $728.1 million, or $43.75 per share. The investigation\nconcerns whether the Capital Board breached its fiduciary duties to\nshareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/capital-bancorp-inc-nasdaq-cbnk/.\n\nLifecore Biomedical, Inc. (Nasdaq – LFCR)\n\nUnder the terms of the Merger Agreement, Lifecore Biomedical will be acquired\nby Webster Equity Partners for $6.28 per share in cash at closing plus one\nnon-tradable contingent value right (CVR) per share. The investigation\nconcerns whether the Lifecore Biomedical Board breached its fiduciary duties\nto shareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/lifecore-biomedical-inc-nasdaq-lfcr/.\n\nMISTRAS Group, Inc. (NYSE – MG)\n\nUnder the terms of the Merger Agreement, MISTRAS Group will be acquired by\naffiliates of H.I.G. Capital for $20.35 per share in an all-cash transaction,\nrepresenting an enterprise value of approximately $866 million, including\noutstanding debt. The investigation concerns whether the MISTRAS Group Board\nbreached its fiduciary duties to shareholders by failing to conduct a fair\nprocess, including whether the proposed transaction is paying fair value to\nshareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/mistras-group-inc-nyse-mg/.\n\nUtz Brands, Inc. (NYSE – UTZ)\n\nUnder the terms of the Merger Agreement, Utz will be acquired by Intersnack\nGroup GmbH & Co. KG (“Intersnack”) for $14.25 per share in cash\nrepresenting an enterprise value of approximately $2.9 billion. The\ninvestigation concerns whether the Utz Board breached its fiduciary duties to\nshareholders by failing to conduct a fair process, including whether the\nproposed transaction is paying fair value to shareholders of the Company.\n\nAdditional information can be found at\nhttps://www.brodskysmith.com/cases/utz-brands-inc-nyse-utz/.\n\nBrodsky & Smith is a litigation law firm with extensive expertise representing\nshareholders throughout the nation in securities and class action lawsuits.\nThe attorneys at Brodsky & Smith have been appointed by numerous courts\nthroughout the country to serve as lead counsel in class actions and have\nsuccessfully recovered millions of dollars for our clients and shareholders.\nAttorney advertising. Prior results do not guarantee a similar outcome.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/aeea7200-7231-49dd-b4ba-ec680464b28c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T18:04:02.14544675Z","server_sent_at_ms":1790791442145},"received_at":"2026-09-30T18:04:02.282Z","source_url":null},"analysis":{"id":"145851","press_release_id":"157178","analysis_json":{"industry":{"label":"Banks","sector":"Financials"},"redFlags":[],"eventType":"legal_litigation","narrative":"Brodsky & Smith issued a shareholder-solicitation notice announcing investigations into several pending mergers, including Capital Bancorp's acquisition by Peoples Bancorp.\n\nFor CBNK, the deal terms are 1.11 Peoples shares per Capital share, worth roughly $43.75 per share ($728.1 million aggregate) based on Peoples' 20-day VWAP of $39.41.\n\nThe firm is investigating whether the Capital board breached fiduciary duties by failing to secure fair value. This is law-firm marketing, not an issuer disclosure or court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm merger investigation solicitation -- suppress."},"keyFigures":{"customDimensions":{"exchange_ratio":"1.11 Peoples shares per CBNK share","transaction_value":"$728.1 million","implied_per_share_value":"$43.75 per share"}},"quotedText":"","namedEntities":{"people":[{"name":"Jason Brodsky","role":"law firm contact"},{"name":"Marc Ackerman","role":"law firm contact"}],"products":[],"companies":[{"name":"Brodsky & Smith","relationship":"plaintiff law firm"},{"name":"Capital Bancorp, Inc.","ticker":"CBNK","relationship":"investigation target / merger target"},{"name":"Peoples Bancorp Inc.","ticker":"PEBO","relationship":"acquirer"},{"name":"Lifecore Biomedical, Inc.","ticker":"LFCR","relationship":"investigation target"},{"name":"Webster Equity Partners","relationship":"acquirer of Lifecore"},{"name":"MISTRAS Group, Inc.","ticker":"MG","relationship":"investigation target"},{"name":"H.I.G. Capital","relationship":"acquirer of MISTRAS"},{"name":"Utz Brands, Inc.","ticker":"UTZ","relationship":"investigation target"},{"name":"Intersnack Group GmbH & Co. KG","relationship":"acquirer of Utz"}],"dollarAmounts":[{"amount":"$728.1 million","context":"aggregate value of Peoples Bancorp acquisition of Capital Bancorp"},{"amount":"$43.75","context":"per-share value to CBNK shareholders based on Peoples 20-day VWAP"},{"amount":"$39.41","context":"Peoples 20-day VWAP as of September 29, 2026"},{"amount":"$6.28","context":"per-share cash consideration for Lifecore Biomedical"},{"amount":"$20.35","context":"per-share cash consideration for MISTRAS Group"},{"amount":"$866 million","context":"MISTRAS enterprise value"},{"amount":"$14.25","context":"per-share cash consideration for Utz Brands"},{"amount":"$2.9 billion","context":"Utz enterprise value"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Brodsky & Smith regarding a pending merger investigation into CBNK. No certified class, no settlement, no new issuer disclosure; boilerplate investor-rights marketing."},"tickerRelevance":{"others":[{"ticker":"PEBO","relevance":"acquirer"},{"ticker":"LFCR","relevance":"co-investigation target"},{"ticker":"MG","relevance":"co-investigation target"},{"ticker":"UTZ","relevance":"co-investigation target"}],"primary":"CBNK"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Brodsky & Smith issued a shareholder-solicitation notice announcing investigations into several pending mergers, including Capital Bancorp's acquisition by Peoples Bancorp.\n\nFor CBNK, the deal terms are 1.11 Peoples shares per Capital share, worth roughly $43.75 per share ($728.1 million aggregate) based on Peoples' 20-day VWAP of $39.41.\n\nThe firm is investigating whether the Capital board breached fiduciary duties by failing to secure fair value. This is law-firm marketing, not an issuer disclosure or court action; treat as low-signal noise.","key_figures":{"customDimensions":{"exchange_ratio":"1.11 Peoples shares per CBNK share","transaction_value":"$728.1 million","implied_per_share_value":"$43.75 per share"}},"named_entities":{"people":[{"name":"Jason Brodsky","role":"law firm contact"},{"name":"Marc Ackerman","role":"law firm contact"}],"products":[],"companies":[{"name":"Brodsky & Smith","relationship":"plaintiff law firm"},{"name":"Capital Bancorp, Inc.","ticker":"CBNK","relationship":"investigation target / merger target"},{"name":"Peoples Bancorp Inc.","ticker":"PEBO","relationship":"acquirer"},{"name":"Lifecore Biomedical, Inc.","ticker":"LFCR","relationship":"investigation target"},{"name":"Webster Equity Partners","relationship":"acquirer of Lifecore"},{"name":"MISTRAS Group, Inc.","ticker":"MG","relationship":"investigation target"},{"name":"H.I.G. Capital","relationship":"acquirer of MISTRAS"},{"name":"Utz Brands, Inc.","ticker":"UTZ","relationship":"investigation target"},{"name":"Intersnack Group GmbH & Co. KG","relationship":"acquirer of Utz"}],"dollarAmounts":[{"amount":"$728.1 million","context":"aggregate value of Peoples Bancorp acquisition of Capital Bancorp"},{"amount":"$43.75","context":"per-share value to CBNK shareholders based on Peoples 20-day VWAP"},{"amount":"$39.41","context":"Peoples 20-day VWAP as of September 29, 2026"},{"amount":"$6.28","context":"per-share cash consideration for Lifecore Biomedical"},{"amount":"$20.35","context":"per-share cash consideration for MISTRAS Group"},{"amount":"$866 million","context":"MISTRAS enterprise value"},{"amount":"$14.25","context":"per-share cash consideration for Utz Brands"},{"amount":"$2.9 billion","context":"Utz enterprise value"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T18:04:08.090Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":5797,"modelName":"glm-5.3-flashx"}}